Skip to content

Regenxbio RGNX Price / book

Price / book at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
2.6×+0.2×
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
1.5×-3.9×
Biogen logo
BiogenBIIB
1.4×+0.3×
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
1.7×-0.6×
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
4.7×+3.4×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
316.5×+303×

Other financials

Income statement

See full
Revenue$6.4M-92.8%
Gross profit$14.9M+35.7%
Operating income-$83.4M-787%
Net income-$90.1M-1,580%
EPS (diluted)-$1.72-1,533%

Balance sheet

See full
Cash & equivalents$15.2M-88.3%
Total debt$71.1M-11.0%
Total equity$21.1M-92.3%
Total assets$341.9M-30.4%

Cash flow

See full
Operating cash flow-$76.2M-327%
CapEx$1.2M+20.6%
Free cash flow-$77.4M-337%

Valuation

See full
Market cap$529.38M+24.6%
Enterprise value$585.22M+56.3%
P/S+3.3×

Profitability

See full
Gross margin59.7%+1.0pp
Operating margin-292.3%-613pp
Net margin-330.2%-588pp
FCF margin-269.2%-364pp

Returns & leverage

See full
Return on equity-196.4%-288pp
Debt / equity3.4×+3.1×
Current ratio2.6×-0.3×

Where this comes from

Calculated from Regenxbio’s reported figures.

Based on the most recent quarter.

The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regenxbio's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Regenxbio's price / book?
Regenxbio (RGNX) reported price / book of 20.5× in Q1 2026.
How has Regenxbio's price / book changed year-over-year?
Regenxbio's price / book increased by 1470.8% year-over-year, from 1.3× to 20.5×.
What is the long-term trend for Regenxbio's price / book?
Over 5 years (2020 to 2025), Regenxbio's price / book has grown at a 6.7% compound annual growth rate (CAGR), from 5.1× to 7.1×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.